Nucleic acid releasing agent for on-site rapid detection of hantavirus, detection method and application
By using a specific composition of nucleic acid release agent, the problems of cumbersome nucleic acid extraction operations and unsatisfactory sample processing in Hantavirus detection are solved, and the rapid, complete and sensitive detection of Hantavirus is achieved, adapting to the needs of rapid on-site detection.
Patent Information
- Application Number
- CN202411373231.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-29
- Publication Date
- 2024-11-26
AI Technical Summary
The existing hantavirus detection methods, especially nucleic acid detection methods, have problems such as cumbersome nucleic acid extraction operations, unsatisfactory sample processing results and long detection time, making it difficult to adapt to the needs of rapid on-site testing.
Provide a nucleic acid release agent, including adenose, guanidine isothiocyanate, ethylenediaminetetraacetic acid and alkylphenol polyoxyethylene ether in a specific mass ratio, which can maintain the stability of the nucleic acid molecule and fully release the RNA in the hantavirus. , and has anti-inhibitory properties, so that the obtained nucleic acid extract can be directly used for RT-qPCR detection.
It realizes rapid, complete and sensitive detection of Hantavirus, simplifies operations, shortens detection time, and adapts to the needs of rapid on-site detection.
Smart Images

Figure BDA0005068107620000021 
Figure BDA0005068107620000022 
Figure BDA0005068107620000051
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of molecular biological detection, and in particular relates to a nucleic acid release agent, a detection method and an application thereof for on-site rapid detection of Hantavirus. Background Art
[0002] Hemorrhagic fever with renal syndrome (HFRS) is an infectious disease caused by Hantavirus infection, which has the characteristics of rapid disease progression, unclear clinical staging, easy misdiagnosis, and high mortality, which seriously threatens public health and safety. Therefore, it is of great significance to establish a method for early and accurate detection of Hantavirus, which is conducive to the early diagnosis and timely and effective treatment of HFRS.
[0003] Hantavirus belongs to the genus Orthohantavirus and the family Hantaviridae of the order Bunyavirales. It is an enveloped, segmented, negative-strand RNA virus. Its genetic structure is divided into L, M, and S. These three segments encode RNA polymerase protein, envelope glycoprotein, and nucleocapsid protein, respectively.
[0004] At present, the detection methods of Hantavirus infection mainly include virus isolation detection method, serum detection method and nucleic acid detection method. Among them, the virus isolation detection method refers to inoculating the sample into susceptible cell culture, and confirming the presence of Hantavirus by observing whether Hantavirus reproduces in the cells. It is the "gold standard" for diagnosing viral infection. However, the virus isolation detection method is limited by technology and safety, and it is difficult to achieve rapid on-site detection. The immunoassay method refers to the use of antibodies that have specific recognition ability for Hantavirus antigenic determinants to confirm the presence of Hantavirus. However, the serum detection method has problems such as low sensitivity, poor specificity and easy missed detection. The nucleic acid detection method refers to the use of specific primers and PCR reactions to achieve specific amplification of Hantavirus genes in samples. Hantavirus can be detected in the early stages of infection, which is a more ideal detection method.
[0005] In DNA and / or RNA templates, the quality of nucleic acid templates greatly affects the test results, so it is necessary to perform multiple steps of nucleic acid extraction operations on the collected samples to purify high-quality DNA and / or RNA templates. However, the steps of nucleic acid extraction operations are cumbersome, and the introduced extraction reagents may also cause the nucleic acid to break, degrade, and inhibit the PCR reaction. There are problems such as cumbersome operations, unsatisfactory sample processing effects, and long detection time. It cannot well meet the needs of rapid on-site detection of Hantavirus and has great limitations. Summary of the invention
[0006] The first purpose of the present invention is to provide a nucleic acid releaser for rapid detection of Hantavirus. The nucleic acid releaser can keep the nucleic acid molecules stable and intact while fully releasing the RNA in Hantavirus to obtain a nucleic acid extract containing a high-quality RNA template; and the nucleic acid releaser has excellent anti-inhibition ability, so that the obtained nucleic acid extract can be directly subjected to RT-qPCR detection without other treatment, which can well meet the needs of rapid on-site detection of Hantavirus and has great application prospects.
[0007] The second object of the present invention is to provide a method for detecting Hantavirus.
[0008] The third object of the present invention is to provide the use of the above-mentioned nucleic acid releasing agent in rapid on-site detection of Hantavirus for non-diagnostic purposes.
[0009] Specifically, the nucleic acid releaser for rapid detection of Hantavirus provided by the present invention includes aldohexose, guanidine isothiocyanate, ethylenediaminetetraacetic acid and alkylphenol polyoxyethylene ether in a mass ratio of (10-100):(0.1-5):(1-10):(10-100).
[0010] Furthermore, the aldohexose includes one or more of allose, glucose, mannose and gulose.
[0011] Furthermore, the structure of the alkylphenol polyoxyethylene ether is shown in formula (1):
[0012]
[0013] In formula (1), R is a C5-10 straight-chain alkyl group or a C5-10 branched-chain alkyl group, and n=5-10.
[0014] Furthermore, the alkylphenol polyoxyethylene ether is 2,2,4-trimethylpentylphenol polyoxyethylene ether, and the structure of the 2,2,4-trimethylpentylphenol polyoxyethylene ether is shown in formula (2):
[0015]
[0016] In formula (2), n=7-10.
[0017] Furthermore, the nucleic acid releaser comprises aldohexose, guanidine isothiocyanate, ethylenediaminetetraacetic acid and alkylphenol polyoxyethylene ether in a mass ratio of (75-150):(1.5-3):(2-12):(1-2), and the aldohexose is mannose and / or gulose.
[0018] Furthermore, the nucleic acid releaser comprises mannose, guanidine isothiocyanate, ethylenediaminetetraacetic acid and 2,2,4-trimethylpentylphenol polyoxyethylene ether in a mass ratio of (30-75):(0.5-1.5):(1-7.5):(50-100).
[0019] The detection method of Hantavirus provided by the present invention comprises: mixing a sample liquid to be tested with the above-mentioned nucleic acid release agent to obtain a nucleic acid extract; mixing the nucleic acid extract with a PCR reaction agent, performing RT-qPCR amplification, and obtaining a detection result.
[0020] Furthermore, based on the total volume of the sample to be tested, the added amount of the nucleic acid releasing agent is 100-500 μg / μL.
[0021] Furthermore, the PCR reagent includes a Tris-HCl buffer with a pH of 7.5 to 8.5, dNTPs, a complex enzyme composition, a soluble magnesium salt and a primer probe composition.
[0022] Furthermore, the dNTPs include dATP, dCTP, dGTP, dTTP and dUTP in a molar ratio of (36-73):(0.8-1.5):(1.1-6):(50-100).
[0023] Furthermore, the complex enzyme composition comprises UNG enzyme, Taq enzyme and reverse transcriptase in an enzyme activity ratio of (0.01-0.1):(0.1-5):(1-15).
[0024] Furthermore, the soluble magnesium salt includes magnesium sulfate and / or magnesium chloride.
[0025] Furthermore, the primer-probe composition comprises a forward primer with a sequence as described in SEQ ID NO:1, a reverse primer with a sequence as described in SEQ ID NO:2, and a fluorescent probe with a sequence as described in SEQ ID NO:3.
[0026] Furthermore, in the RT-qPCR amplification, the added concentration of the nucleic acid extract is 5 to 50% (v / v), the added concentration of the Tris-HCl buffer is 10 to 20 mM, the added concentration of the dNTP is 0.1 to 1.5 mM, the added concentration of the complex enzyme composition is 0.5 to 2.5 U / μL, the added concentration of the soluble magnesium salt is 1 to 4 mM, and the added concentration of the primer probe composition is 2 to 15 μM.
[0027] The present invention also provides the use of the nucleic acid releasing agent in rapid on-site detection of Hantavirus for non-diagnostic purposes.
[0028] Beneficial effects:
[0029] The composition for rapid detection of Hantavirus provided by the present invention includes a nucleic acid releaser for processing the sample to be tested, and the nucleic acid releaser includes a specific mass ratio of hexose, guanidine isothiocyanate, ethylenediaminetetraacetic acid and alkylphenol polyoxyethylene ether. After mixing it with the sample to be tested, the nucleic acid in the sample to be tested can be quickly, fully and completely released to obtain a nucleic acid extract containing a high-quality nucleic acid template. The nucleic acid releaser also has good anti-inhibition performance. The obtained nucleic acid extract is directly used for PCR amplification to achieve an ideal amplification effect. The composition is used to detect Hantavirus in the sample to be tested, which has the advantages of simple operation, short time, high sensitivity and reliability, etc. It can well meet the needs of rapid on-site detection of Hantavirus and has great application prospects.
[0030] It is speculated that the reason why the composition for rapid detection of Hantavirus provided by the present invention has the above-mentioned effects is: first, the nucleic acid releaser can quickly and fully dissolve and denature the protein through the synergistic cooperation between the components in a specific mass ratio, and the aldohexose therein will undergo complex ring opening and closing reactions, isomerization reactions and other reactions under the action of other substances in the nucleic acid releaser and / or factors such as the temperature change conditions of the PCR reaction. The occurrence of these reactions can well stabilize the structure of the RNA molecule, reduce the breakage and degradation of the RNA molecule during nucleic acid release and RT-qPCR amplification, so that the RNA molecules in the Hantavirus are quickly, fully and completely released, and have excellent nucleic acid release performance; secondly, the aldohexose, guanidine isothiocyanate, ethylenediaminetetraacetic acid and alkylphenol polyoxyethylene ether in the nucleic acid releaser constitute an organic whole, which work together to maintain the sufficient free state of the RNA template during the RT-qPCR process and reduce the degradation of the RNA template and the probe, and at the same time effectively reduce the adverse effects of related inhibitory substances in the sample to be tested on the activity of DNA polymerase, the binding of the template with primers and the probe, and have excellent anti-inhibition performance. DETAILED DESCRIPTION
[0031] The nucleotide sequences involved in the present invention are shown in Table 1.
[0032] Table 1.
[0033] name SEQ ID NO: Specific Information Hantavirus-Forward Primer 1 CAGCAAGTGCAGCAGAA Hantavirus-Reverse Primer 2 GTCTAATTCAAGATCTGTATGCAT Hantavirus-fluorescent probe 3 5'-HEX-ACAGATAATGCACATGGCGTTG-BHQ1-3'
[0034] Based on the purpose of achieving rapid on-site detection of Hantavirus, the present invention provides a nucleic acid releaser for rapid detection of Hantavirus, specifically including aldohexose, guanidine isothiocyanate, ethylenediaminetetraacetic acid and alkylphenol polyoxyethylene ether in a ratio of (10-100):(0.1-5):(1-10):(10-100), such as 10:0.1:1:10, 10:5:1:100, 23:5:8:100, 100:3:9:70, 100:3:9:100 or any value therebetween.
[0035] In the present invention, the aldohexose is a monosaccharide containing 6 carbon atoms, which can undergo structural changes such as ring opening and closing reactions and isomerization reactions, and specifically includes one or more of allose, glucose, mannose and gulose. In some specific embodiments, the aldohexose preferably includes one or more of D-allose, D-glucose, D-mannose and D-gulose.
[0036] In the present invention, the alkylphenol polyoxyethylene ether is an organic compound containing an alkylphenol group and a polyoxyethylene ether structural monomer, and the structure is specifically as shown in formula (1):
[0037]
[0038] In formula (1), R is a C5-10 straight-chain alkyl group or a C5-10 branched-chain alkyl group; n=5-10, such as 5, 6, 8, 9, 10 or any integer therebetween. Specific examples of the C5-10 straight-chain alkyl group include, but are not limited to, one or more of -(CH2)4CH3, -(CH2)6CH3, and -(CH2)9CH3. Specific examples of the C5-10 branched-chain alkyl group include, but are not limited to, one or more of -CH(CH3)(CH2)4CH3, -(CH2)5CH(CH3)CH3, and -C(CH3)2CH2C(CH3)3.
[0039] In some specific embodiments, the alkylphenol polyoxyethylene ether is preferably 2,2,4-trimethylpentylphenol polyoxyethylene ether, and the structure of the 2,2,4-trimethylpentylphenol polyoxyethylene ether is as shown in formula (2):
[0040]
[0041] In formula (2), n=7-10.
[0042] In some specific embodiments, the nucleic acid releaser preferably includes aldohexose, guanidine isothiocyanate, ethylenediaminetetraacetic acid and alkylphenol polyoxyethylene ether in a mass ratio of (30-75):(0.5-1.5):(1-7.5):(50-100), and the aldohexose is mannose and / or gulose.
[0043] In some specific embodiments, the nucleic acid releaser more preferably includes mannose, guanidine isothiocyanate, ethylenediaminetetraacetic acid and 2,2,4-trimethylpentylphenol polyoxyethylene ether in a mass ratio of (36-73):(0.8-1.5):(1.1-6):(50-100).
[0044] In the present invention, the nucleic acid releaser can be pre-mixed with the sample solution to be tested and then added to the PCR reagent at the same time, or it can be added to the PCR reagent before the sample solution to be tested is added, or it can be added to the PCR reagent after the sample solution to be tested is added. That is, the present invention does not impose any particular limitation on the use of the nucleic acid releaser, and those skilled in the art can make adaptive adjustments according to the actual needs of use.
[0045] Based on the purpose of better realizing the rapid on-site detection of Hantavirus, the present invention also provides a method for detecting Hantavirus, in which the nucleic acid release agent and the sample liquid to be tested are preferably mixed in advance and then added to the PCR reagent at the same time. The detection method specifically comprises: mixing the sample liquid to be tested with the nucleic acid release agent to obtain a nucleic acid extract; mixing the nucleic acid extract with the PCR reagent, performing RT-qPCR amplification, and obtaining the detection result.
[0046] In the present invention, based on the total volume of the sample to be tested, the added amount of the nucleic acid releaser is preferably 100-500 μg / μL, such as 100 μg / μL, 120 μg / μL, 150 μg / μL, 160 μg / μL, 200 μg / μL, 250 μg / μL, 300 μg / μL, 600 μg / μL or any value therebetween.
[0047] In the present invention, the PCR reagent is a composition capable of realizing in vitro amplification of RNA molecules, which specifically comprises: Tris-HCl buffer with pH=7.5-8.5, dNTP, complex enzyme composition, soluble magnesium salt and primer probe composition.
[0048] In the present invention, in the PCR reactants, the dNTPs preferably include dATP, dCTP, dGTP, dTTP and dUTP in a molar ratio of (0.8-1.2):(0.8-1.2):(0.8-1.2):(0.8-1.2):(0.8-1.2), such as 0.8:1:1:1:1, 1:1:1:1:1, 1.2:1:0.8:1:1, 1.2:0.8:0.9:1:1 or any value therebetween.
[0049] In the present invention, in the PCR reaction agent, the complex enzyme composition preferably includes UNG enzyme, Taq enzyme and reverse transcriptase with an enzyme activity ratio of (0.01-0.1):(0.1-5):(1-15), such as 0.01:1:10, 0.018:3:13, 0.08:10:13, 0.1:10:15 or any value therebetween.
[0050] In the present invention, in the PCR reagent, specific examples of the soluble magnesium salt may be, but are not limited to, one or more of magnesium sulfate, magnesium chloride and magnesium nitrate. In some specific embodiments, the soluble magnesium salt preferably includes magnesium sulfate and / or magnesium chloride.
[0051] In the present invention, in the PCR reaction agent, the primer-probe composition preferably includes a forward primer as described in SEQ ID NO: 1, a reverse primer as described in SEQ ID NO: 2, and a fluorescent probe as described in SEQ ID NO: 3. Wherein, the fluorescent probe refers to an oligonucleotide that can specifically identify a specific nucleotide fragment on the Hantavirus genome and has a fluorescent group and a quenching group connected to both ends, respectively, to achieve qualitative and / or quantitative detection of Hantavirus. More specifically, specific examples of the fluorescent group include but are not limited to: one or more of FAM, TET, JOE, HEX, CY3, TAMRA, ROX, TexasRed, VIC, HEX and ROX; specific examples of the quenching group include but are not limited to: one or more of BHQ-0, BHQ-1, BHQ-2, Dabcyl, Eclipse and TAMRA.
[0052] In the present invention, in the reaction system of RT-qPCR amplification, the added concentration of the nucleic acid extract is preferably 5-50% (v / v), such as 5% (v / v), 7.5% (v / v), 20% (v / v), 45% (v / v), 50% (v / v) or any value therebetween; the added concentration of the Tris-HCl buffer is preferably 10-20 mM, such as 10 mM, 11 mM, 13 mM, 15.5 mM, 18 mM, 20 mM or any value therebetween; the added concentration of dNTP is preferably 0.1-1.5 mM, such as 0.1 mM, 0.15 mM, 0.3 mM, 0.5mM, 1.2mM, 1.5mM or any value therebetween; the added concentration of the complex enzyme composition is preferably 0.5-2.5U / μL, such as 0.5, 0.8, 1.3, 1.5, 2, 2.5 or any value therebetween; the added concentration of the soluble magnesium salt is preferably 1-4mM, such as 1mM, 1.3mM, 1.5mM, 2mM, 2.3mM, 3mM, 4mM or any value therebetween; the added concentration of the primer probe composition is preferably 2-15μM, such as 2μM, 2.5μM, 4μM, 5μM, 9μM, 10μM, 15μM or any value therebetween.
[0053] The present invention also provides the use of the nucleic acid releasing agent in rapid on-site detection of Hantavirus for non-diagnostic purposes.
[0054] Embodiments of the present invention are described in detail below, and the examples of the embodiments are intended to be used to explain the present invention, but should not be construed as limiting the present invention. In the embodiments, if specific techniques or conditions are not specified, the techniques or conditions described in the literature in this area or the product specifications are used. If the manufacturer is not specified for reagents or instruments used, they are all conventional products that can be obtained commercially.
[0055] The reagents and their sources involved in the following examples specifically include:
[0056] D-mannose (Aladdin, catalog number M103970);
[0057] Triton X-100 (Aladdin, item number T109026);
[0058] D-glucose (Source Leaf Biotechnology, product number S11022);
[0059] D-allose (Yuanye Biotechnology, product number S45219);
[0060] D-gulose (Source Leaf Biotechnology, product number B71080);
[0061] Triton X-114 (Yisheng Biological, product number 20108ES76);
[0062] NP-40 (Yisheng Biological, product number 20103ES60);
[0063] Tween 20 (Aladdin, catalog number T434505);
[0064] UNG enzyme (Shengyi (Xiamen) Biotechnology Co., Ltd., catalog number CTT09872);
[0065] Taq enzyme (Shengyi (Xiamen) Biotechnology Co., Ltd., catalog number CTAQ001);
[0066] Reverse transcriptase (Shengyi (Xiamen) Biotechnology Co., Ltd., catalog number CMMLV002);
[0067] Hantavirus (Shanghai Biotechnology Co., Ltd., catalog number SG99876).
[0068] Example 1
[0069] This example is used to illustrate a nucleic acid releasing agent, which includes 36 parts by mass of D-mannose, 0.8 parts by mass of guanidine isothiocyanate, 1.1 parts by mass of ethylenediaminetetraacetic acid, and 61.8 parts by mass of Triton X-100.
[0070] Example 2
[0071] This example is used to illustrate a nucleic acid releasing agent, which includes 40.2 parts by mass of D-mannose, 0.78 parts by mass of guanidine isothiocyanate, 3.24 parts by mass of ethylenediaminetetraacetic acid, and 55.78 parts by mass of Triton X-100.
[0072] Example 3
[0073] This example is used to illustrate a nucleic acid releasing agent, which includes 21.75 parts by mass of D-mannose, 0.36 parts by mass of guanidine isothiocyanate, 5.43 parts by mass of ethylenediaminetetraacetic acid, and 72.46 parts by mass of Triton X-100.
[0074] Example 4
[0075] This example is used to illustrate a nucleic acid releasing agent, which includes 49.73 parts by mass of D-mannose, 0.05 parts by mass of guanidine isothiocyanate, 0.5 parts by mass of ethylenediaminetetraacetic acid, and 49.72 parts by mass of Triton X-100.
[0076] Example 5
[0077] This example is used to illustrate a nucleic acid releasing agent, which includes 8 parts by mass of D-mannose, 4 parts by mass of guanidine isothiocyanate, 8 parts by mass of ethylenediaminetetraacetic acid, and 80 parts by mass of Triton X-100.
[0078] Example 6
[0079] The nucleic acid releasing agent provided in this example is basically the same as that in Example 1, except that an equal amount of D-glucose is used instead of D-mannose, and other conditions are the same to obtain a nucleic acid releasing agent.
[0080] Example 7
[0081] The nucleic acid releasing agent provided in this example is substantially the same as that in Example 1, except that an equal amount of D-allose is used instead of D-mannose, and other conditions are the same to obtain a nucleic acid releasing agent.
[0082] Example 8
[0083] The nucleic acid releasing agent provided in this example is substantially the same as that in Example 1, except that an equal amount of D-gulose is used instead of D-mannose, and other conditions are the same to obtain a nucleic acid releasing agent.
[0084] Example 9
[0085] The nucleic acid releasing agent provided in this example is substantially the same as that in Example 1, except that an equal amount of Triton X-114 is used instead of Triton X-100, and other conditions are the same to obtain a nucleic acid releasing agent.
[0086] Example 10
[0087] The nucleic acid releasing agent provided in this example is substantially the same as that in Example 1, except that an equal amount of NP-40 is used instead of Triton X-100, and other conditions are the same to obtain a nucleic acid releasing agent.
[0088] Comparative Example 1
[0089] The nucleic acid releaser provided in this comparative example is basically the same as that in Example 1, except that an equal amount of Triton X-100 is used instead of D-mannose, and other conditions are the same to obtain a nucleic acid releaser.
[0090] Comparative Example 2
[0091] The nucleic acid releaser provided in this comparative example is basically the same as that in Example 1, except that an equal amount of mannitol is used instead of D-mannose, and other conditions are the same to obtain a nucleic acid releaser.
[0092] Comparative Example 3
[0093] The nucleic acid releaser provided in this comparative example is basically the same as that in Example 1, except that an equal amount of D-mannose is used instead of Triton X-100, and other conditions are the same to obtain a nucleic acid releaser.
[0094] Comparative Example 4
[0095] The nucleic acid releaser provided in this comparative example is basically the same as that in Example 1, except that an equal amount of Tween-20 is used instead of Triton X-100, and other conditions are the same to obtain a nucleic acid releaser.
[0096] Comparative Example 5
[0097] The nucleic acid releaser provided in this comparative example is basically the same as that in Example 1, except that an equal amount of Triton X-100 is used instead of guanidine isothiocyanate, and other conditions are the same to obtain a nucleic acid releaser.
[0098] Comparative Example 6
[0099] The nucleic acid releaser provided in this comparative example is basically the same as that in Example 1, except that an equal amount of Triton X-100 is used instead of ethylenediaminetetraacetic acid, and other conditions are the same to obtain a nucleic acid releaser.
[0100] Test Example 1
[0101] This test is used to illustrate the detection sensitivity of the nucleic acid release agents provided in the above embodiments and comparative examples for RT-qPCR detection of Hantavirus. The test specifically includes:
[0102] (1) According to Table 2, Hantaan pseudovirus was mixed with a respiratory swab known to be negative for Hantaan virus to prepare a sample solution with different virus concentrations, and 250 μg of nucleic acid release agent was mixed with 1 μL of the sample solution to obtain a nucleic acid extract.
[0103] Table 2.
[0104]
[0105] (2) The nucleic acid extract obtained in (1) was subjected to RT-qPCR detection using a rapid PCR instrument AP-400 (Anbang Biotechnology), and the PCR reaction system and amplification procedure are specifically shown in Table 3.
[0106] Table 3.
[0107]
[0108] Each group of samples was tested 20 times, and the positive detection rate (unit: %) was calculated according to the following formula. The test results are shown in Table 4.
[0109] Detection positive rate = positive samples / total number of samples × 100%
[0110] Among them, positive samples are judged based on the CT value. When the CT value is less than 38, it is judged as a positive sample, otherwise it is excluded.
[0111] Table 4.
[0112]
[0113] It can be seen from the test results shown in Table 4 that compared with the nucleic acid releasers provided in Comparative Examples 1 to 6, the nucleic acid releasers provided in Examples 1 to 10 of the present invention have a good release effect on the RNA molecules in Hantaan pseudovirus, and can effectively, fully and completely extract RNA molecules. The nucleic acid releaser has good nucleic acid protection and anti-inhibition effects when applied to RT-qPCR reactions. It also has a 100% positive detection rate for positive sample 1 with a virus concentration of only 50 copy / mL, and no positive is detected in negative samples, with excellent sensitivity and reliability.
[0114] Test Example 2
[0115] This test is used to illustrate the anti-interference performance of the nucleic acid release agent provided in the above Example 1 and the comparative example when applied to RT-qPCR detection of Hantavirus. The test specifically includes:
[0116] (1) Hantaan pseudovirus was mixed with a respiratory swab known to be negative for Hantaan virus to prepare a test sample solution with a virus concentration of 1000 copy / mL, and various interfering substances were added according to Table 4. Then, 250 μg of nucleic acid release agent was mixed with 1 μL of the test sample solution to obtain a nucleic acid extract.
[0117] (2) Rapid PCR instrument AP-400 was used to perform RT-qPCR on the nucleic acid extract obtained in (1), and the PCR reaction system and amplification procedure were the same as those in Test Example 1, and each group was repeated 20 times to calculate the positive detection rate of each clinical positive sample and negative sample. The test results are shown in Table 5.
[0118] Table 5.
[0119]
[0120] It can be seen from the test results shown in Table 5 that compared with the nucleic acid releasers provided in Comparative Examples 1 to 6, the nucleic acid releaser provided by the present invention is used to treat the test samples, and has excellent anti-interference effects on commonly used clinical drugs such as α-interferon, ribavirin, peramivir, oxymetazoline and beclomethasone.
[0121] Test Example 3
[0122] This test is used to illustrate the detection performance of the nucleic acid release agents provided in the above embodiments and comparative examples in RT-qPCR detection of Hantavirus complex clinical samples. The test specifically includes:
[0123] (1) According to Table 6, a clinical plasma sample known to be positive for Hantavirus was diluted with nuclease-free water to prepare a test sample solution with different virus concentrations, and 500 μg of nucleic acid release agent was mixed with 1 μL of the test sample solution to obtain a nucleic acid extract.
[0124] Table 6.
[0125]
[0126] (2) Rapid PCR instrument AP-400 was used to perform RT-qPCR on the nucleic acid extract obtained in (1), and the PCR reaction system and amplification procedure were the same as those in Test Example 1, and each group was repeated 20 times to calculate the positive detection rate of each clinical positive sample and negative sample. The test results are shown in Table 7.
[0127] Table 7.
[0128]
[0129] It can be seen from the test results shown in Table 7 that compared with the nucleic acid releasers provided in Comparative Examples 1 to 6, the nucleic acid releasers provided in Examples 1 to 10 of the present invention are used to process complex plasma samples, and the positive detection rates of clinical positive samples with different virus concentrations are all higher than 80%, and when the virus concentration in the clinical positive samples is higher than 500 copy / mL, the positive detection rate is 100%, and clinical plasma samples known to be negative for Hantavirus are basically not detected as positive, which has very excellent detection performance.
[0130] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention without departing from the principles and intent of the present invention.
Claims
1. A nucleic acid release agent for rapid detection of Hantavirus, characterized in that: The nucleic acid releaser comprises aldohexose, guanidine isothiocyanate, ethylenediaminetetraacetic acid and alkylphenol polyoxyethylene ether in a mass ratio of (10-100):(0.1-5):(1-10):(10-100).
2. The nucleic acid release agent for rapid detection of Hantavirus according to claim 1, characterized in that: The aldohexose includes one or more of allose, glucose, mannose and gulose.
3. The nucleic acid release agent for rapid detection of Hantavirus according to claim 1, characterized in that: The structure of the alkylphenol polyoxyethylene ether is shown in formula (1): In formula (1), R is a C5-10 straight-chain alkyl group or a C5-10 branched-chain alkyl group, and n=5-10; Optionally, the alkylphenol polyoxyethylene ether is 2,2,4-trimethylpentylphenol polyoxyethylene ether, and the structure of the 2,2,4-trimethylpentylphenol polyoxyethylene ether is as shown in formula (2): In formula (2), n=7-10.
4. The nucleic acid release agent for rapid detection of Hantavirus according to claim 1, characterized in that: The nucleic acid releaser comprises aldohexose, guanidine isothiocyanate, ethylenediaminetetraacetic acid and alkylphenol polyoxyethylene ether in a mass ratio of (30-75):(0.5-1.5):(1-7.5):(50-100), and the aldohexose is mannose and / or gulose; Optionally, the nucleic acid releaser comprises mannose, guanidine isothiocyanate, ethylenediaminetetraacetic acid and 2,2,4-trimethylpentylphenol polyoxyethylene ether in a mass ratio of (36-73):(0.8-1.5):(1.1-6):(50-100).
5. A method for detecting Hantavirus, characterized in that: The detection method comprises: mixing a sample solution to be tested with the nucleic acid release agent according to any one of claims 1 to 4 to obtain a nucleic acid extract; mixing the nucleic acid extract with a PCR reagent, performing RT-qPCR amplification, and obtaining a detection result.
6. The method for detecting Hantavirus according to claim 5, characterized in that: Based on the total volume of the sample to be tested, the added amount of the nucleic acid releasing agent is 100-500 μg / μL.
7. The method for detecting Hantavirus according to claim 5, characterized in that: The PCR reaction agent comprises a Tris-HCl buffer solution with a pH value of 7.5 to 8.5, dNTP, a complex enzyme composition, a soluble magnesium salt and a primer probe composition.
8. The method for detecting Hantavirus according to claim 7, characterized in that: The dNTPs include dATP, dCTP, dGTP, dTTP and dUTP in a molar ratio of (0.8-1.2):(0.8-1.2):(0.8-1.2):(0.8-1.2); Optionally, the complex enzyme composition comprises UNG enzyme, Taq enzyme and reverse transcriptase in an enzyme activity ratio of (0.01-0.1):(0.1-5):(1-15); Optionally, the soluble magnesium salt comprises magnesium sulfate and / or magnesium chloride; Optionally, the primer-probe composition comprises a forward primer with a sequence as described in SEQ ID NO:1, a reverse primer with a sequence as described in SEQ ID NO:2, and a fluorescent probe with a sequence as described in SEQ ID NO:
3.
9. The method for detecting Hantavirus according to claim 7, characterized in that: In the reaction system of the RT-qPCR amplification, the added concentration of the nucleic acid extract is 5 to 50% (v / v), the added concentration of the Tris-HCl buffer is 10 to 20 mM, the added concentration of the dNTP is 0.1 to 1.5 mM, the added concentration of the complex enzyme composition is 0.5 to 2.5 U / μL, the added concentration of the soluble magnesium salt is 1 to 4 mM, and the added concentration of the primer probe composition is 2 to 15 μM.
10. Use of the nucleic acid releasing agent according to any one of claims 1 to 4 in rapid on-site detection of Hantavirus for non-diagnostic purposes.
